Potential Ban on Menthol Cigarettes in the US

Jul.05.2022
Potential Ban on Menthol Cigarettes in the US
A proposed ban on menthol-flavored tobacco products in the US could result in 16,250 fewer tobacco-related deaths by 2060.

In April of last year, the US Food and Drug Administration (FDA) announced a proposed ban on menthol-flavored cigarettes and cigars. This was seen as a measure that could significantly reduce smoking rates.


A recent study published in the BMJ Tobacco Control has concluded that a ban on menthol cigarettes could prevent 16,250 tobacco-related deaths annually by 2060. Epidemiology professor Rafael Meza from the University of Michigan School of Public Health stated that "This work is part of a series of projects aimed at evaluating the impact of a menthol ban on smoking and health. Our findings demonstrate significant health benefits from a menthol ban and emphasize the urgency of its eventual approval and implementation.


The investigation results were based on an analysis of compiled data and computational modeling infrastructure from a portion of the Tobacco Regulatory Science Center. The research team utilized traditional cigarette and electronic cigarette models, which were previously developed simulation models, to study the impact of menthol and non-menthol cigarettes on the behavior of traditional cigarettes and e-cigarettes.


A new study has found that with a ban on menthol cigarettes, the combined smoking of both menthol and non-menthol cigarettes will decrease by 15% by 2026. The study also predicts a decrease in smoking and e-cigarette related deaths by approximately 5%. This reduction in deaths would result in a decrease of 16,250 deaths per year over the course of 40 years.


As such, the FDA has recently announced a ban on menthol, which has been a topic of long-standing debate. The negotiation process has been opened, and comments will be accepted until July 5th.


Canada's Ban on Menthol Cigarettes


Data from Canada shows that a local ban on menthol cigarettes has had a positive impact on smoking cessation rates. Research suggests that, given the popularity of menthol cigarettes in the United States, implementing a similar ban in that country would provide even greater benefits. According to Geoffrey Fong, Chief Investigator of the International Tobacco Control Policy Evaluation Project, "Based on our survey results, we estimate that a ban on menthol cigarettes in the US would lead to an additional 923,000 smokers quitting, including 230,000 African American smokers.


Further data confirms the effectiveness of the ban on menthol cigarettes.


Meanwhile, a recent study published in JAMA Internal Medicine found that the ban on menthol-flavored cigarettes in Massachusetts resulted in a statewide decrease in cigarette sales. The study, titled "Massachusetts' Cigarette Sales and Comprehensive Menthol Ban," reported that after the menthol flavor ban went into effect, cigarette sales in Massachusetts dropped by as much as 33%.


According to researchers, during the same period, cigarette sales decreased by 8% in 33 states that did not implement a ban on menthol flavoring, while sales of menthol-flavored cigarettes decreased by 3%. UPI quoted Samuel Asare, co-author of the Sid study, as saying, "We have learned from Massachusetts that the ban on menthol flavoring effectively reduced sales of menthol and overall cigarettes.


This article has been compiled from third-party information for the purpose of educational exchange. The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19
PMI Expands Colorado Investment to $1.2 Billion to Boost ZYN Nicotine Pouch Production
PMI Expands Colorado Investment to $1.2 Billion to Boost ZYN Nicotine Pouch Production
Philip Morris International (PMI) is expanding its investment in its Golden, Colorado campus, bringing total investment to approximately $1.2 billion to support its smoke-free products business. The investment will strengthen PMI’s research, production and innovation capabilities in smoke-free products. As one of the world’s largest tobacco companies, PMI has continued advancing its “Smoke-Free Future” strategy through heated tobacco, oral nicotine and other reduced-risk product categories.
PMI
Jul.28
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
Yinghe-Controlled Vape Maker SKE Ordered to Post £569,039 Security as It Pursues Crystal Bar Design Infringement Case in UK
The UK High Court has ordered Chinese vape manufacturer Shenzhen SKE Technology to provide £569,039 ($776,000) in security for costs in its design infringement proceedings against Vapepen London and other defendants over its Crystal Bar vape product. The court did not accept the defendants’ main argument that recovering costs from a China-based company would face significant enforcement obstacles, but found that SKE had not sufficiently disclosed its own financial position. The order is procedural and does not determine the underlying infringement claims.
News
Aug.21
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24